EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges

Ina Gajic iD, Nina Tomic iD, Bojana Lukovic, Milos Jovicevic, Dusan Kekic iD, Milos Petrovic, Marko Jankovic iD, Anika Trudic iD, Dragana Mitic Culafic iD, Marina Milenkovic, Natasa Opavski iD

Antibiotics · 21.02.2025 · 14 (3) · 221

DOI: 10.3390/antibiotics14030221 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 21.02.2025. Verfasst von Ina Gajic und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia, Pfizer, Ministry of Science, Technological Development, Innovation of the Republic of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Antimicrobial resistance poses a major public health challenge. The World Health Organization has identified 15 priority pathogens that require prompt development of new antibiotics. This review systematically evaluates the antibacterial resistance of the most significant bacterial pathogens, currently available treatment options, as well as complementary approaches for the management of infections caused by the most challenging multidrug-resistant (MDR) bacteria. For carbapenem-resistant Gram-negative bacteria, treatment options include combinations of beta-lactam antibiotics and beta-lactamase inhibitors, a novel siderophore cephalosporin, known as cefiderocol, as well as older antibiotics like polymixins and tigecycline. Treatment options for Gram-positive bacteria are vancomycin, daptomycin, linezolid, etc. Although the development of new antibiotics has stagnated, various agents with antibacterial properties are currently in clinical and preclinical trials. Non-antibiotic strategies encompass antibiotic potentiators, bacteriophage therapy, antivirulence therapeutics, antimicrobial peptides, antibacterial nanomaterials, host-directed therapy, vaccines, antibodies, plant-based products, repurposed drugs, as well as their combinations, including those used alongside antibiotics. Significant challenges exist in developing new antimicrobials, particularly related to scientific and technical issues, along with policy and economic factors. Currently, most of the alternative options are not part of routine treatment protocols. Conclusions and Future Directions: There is an urgent need to expedite the development of new strategies for treating infections caused by MDR bacteria. This requires a multidisciplinary approach that involves collaboration across research, healthcare, and regulatory bodies. Suggested approaches are crucial for addressing this challenge and should be backed by rational antibiotic use, enhanced infection control practices, and improved surveillance systems for emerging pathogens.

Schlagwörter

Stichwörter der Autor:innen

antimicrobial resistancemultidrug resistancenew antibioticstreatment options

Autor:innen und Institutionen

  • Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
  • Group for Biomedical Engineering and Nanobiotechnology, Institute of Technical Sciences of SASA, Kneza Mihaila 35/IV, 11000 Belgrade, Serbia.
  • Academy of Applied Studies Belgrade, College of Health Sciences, 11000 Belgrade, Serbia.
  • University Clinical Hospital Center "Dr. Dragisa Misovic-Dedinje", 11040 Belgrade, Serbia.
  • Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
  • Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, 21204 Novi Sad, Serbia.

ORCID-Profile: Ina Gajic, Nina Tomic, Dusan Kekic, Marko Jankovic, Anika Trudic, Dragana Mitic Culafic, Natasa Opavski

Förderung

  • Science Fund of the Republic of Serbia
  • Pfizer
  • Ministry of Science, Technological Development, Innovation of the Republic of Serbia

Zitieren

APA

Gajic, I., Tomic, N., Lukovic, B., Jovicevic, M., Kekic, D., Petrovic, M., Jankovic, M., Trudic, A., Mitic Culafic, D., Milenkovic, M., & Opavski, N. (2025). A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges. Antibiotics, 14(3), 221. https://doi.org/10.3390/antibiotics14030221

Vancouver

Gajic I, Tomic N, Lukovic B, Jovicevic M, Kekic D, Petrovic M, et al. A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges. Antibiotics. 2025;14(3):221. doi:10.3390/antibiotics14030221

BibTeX
@article{Gajic2025,
  author = {Gajic, Ina and Tomic, Nina and Lukovic, Bojana and Jovicevic, Milos and Kekic, Dusan and Petrovic, Milos and Jankovic, Marko and Trudic, Anika and Mitic Culafic, Dragana and Milenkovic, Marina and Opavski, Natasa},
  title = {A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges},
  journal = {Antibiotics},
  year = {2025},
  volume = {14},
  number = {3},
  pages = {221},
  doi = {10.3390/antibiotics14030221}
}
Kostenlos starten →